Global Dementia Drugs Market Size to grow at a CAGR of ~8% by 2030, Evaluates DelveInsight

Dementia drugs companies working in the market include Apotex Inc, AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd, Eli Lilly and Company, Johnson and Johnson, Pfizer, Inc., Teva Pharmaceuticals, Zydus Cadila, Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., and Valeant Pharmaceutical International.
(Albany, USA) DelveInsight's "Dementia Drugs Market Insights, Competitive Landscape, and Market Forecast - 2030" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Dementia Drugs companies actively working in the market.

Request for sample report @ Dementia Drugs Market [https://www.delveinsight.com/report-store/dementia-drugs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Dementia Drugs Market are:

* DelveInsight Analysis: The Global Dementia Drugs market size is anticipated to grow with a CAGR of ~8% during the forecasted period (2024-2030).
* Dementia drugs companies working in the market include Apotex Inc, AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd, Eli Lilly and Company, Johnson and Johnson, Pfizer, Inc., Teva Pharmaceuticals, Zydus Cadila, Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., and Valeant Pharmaceutical International and others.
* According to DelveInsight's assessment, the Dementia Drugs market is projected to experience significant growth in the coming years. This surge is attributed to the rising prevalence of patients suffering from dementia, rising government initiative to support the dementia drugs project, technological advancement and launches of Dementia drugs products and growing rise of geriatric population.
* On June 24, 2021, Lilly's donanemb had received the United States FDA's Beakthrough Therapy designation for the treatment of Alzeihmer's disease.
* On June 07, 2021, Aducanumab had received the fast-tracked for approval from Food and Administration for the treatment of Alzheimer's disease (AD).

Dementia Drugs Overview

Dementia drugs are used to manage symptoms of various forms of dementia, such as Alzheimer's disease, vascular dementia, and Lewy body dementia. While there is no cure for dementia, treatments aim to slow the progression of cognitive decline and improve the quality of life for patients.

The main classes of drugs used for dementia include cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by increasing levels of acetylcholine, a chemical important for memory and learning. These drugs are often prescribed for mild to moderate stages of dementia, particularly Alzheimer's.

For more severe stages, memantine, an NMDA receptor antagonist, is used. It helps regulate the activity of glutamate, which plays a crucial role in information processing, memory, and learning. Combination therapy using both classes is sometimes employed.

New drug developments, such as anti-amyloid antibodies like aducanumab, are designed to target the underlying pathology of Alzheimer's by reducing amyloid plaques in the brain. Research into disease-modifying treatments is ongoing, offering hope for more effective interventions in the future. Symptomatic treatments, including antidepressants and antipsychotics, may also be used to manage mood or behavioral issues associated with dementia.

To know more about why North America is leading the market growth in the Dementia Drugs market, get a snapshot of the report Dementia Drugs Market Trends [https://www.delveinsight.com/sample-request/dementia-drugs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Recent Developments in the Dementia Drugs Market Report

* On June 24, 2021, Lilly's donanemb had received the United States FDA's Beakthrough Therapy designation for the treatment of Alzeihmer's disease.
* On June 07, 2021, Aducanumab had received the fast-tracked for approval from Food and Administration for the treatment of Alzheimer's disease (AD).

Dementia Drugs Market Insights

The dementia drugs market is segmented by drug class, indication, distribution channel, and geography. MAO inhibitors are expected to hold a significant market share from 2024 to 2030, thanks to technological advancements. MAO inhibitors, such as isocarboxazid, phenelzine, and selegiline, are strong antidepressants that regulate brain chemicals like serotonin and dopamine, helping in mood regulation for dementia patients.

Alzheimer's disease is anticipated to dominate the indications segment due to its rising prevalence and increased drug approvals. For instance, the FDA approved Biogen's aducanumab for Alzheimer's in 2021. The growing number of drugs in development for Alzheimer's, combined with increasing drug approvals, is expected to drive demand in this market.

Geographically, North America is projected to dominate the dementia drugs market due to its growing elderly population, increased drug approvals, and government initiatives. By 2050, the U.S. population aged 65 and older is expected to grow significantly, further propelling market demand. Additionally, FDA approvals, like Lilly's donanemab in 2021, are boosting the market. These factors, along with increased industry collaborations, are expected to drive market growth during the forecast period.

To read more about the latest highlights related to Dementia Drugs, get a snapshot of the key highlights entailed in the Dementia Drugs Treatment Landscape [https://www.delveinsight.com/report-store/dementia-drugs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Players in the Dementia Drugs Market

Dementia drugs companies working in the market include Apotex Inc, AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd, Eli Lilly and Company, Johnson and Johnson, Pfizer, Inc., Teva Pharmaceuticals, Zydus Cadila, Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., and Valeant Pharmaceutical International and others.

Scope of the Dementia Drugs Market Report

* Coverage: Global
* Study Period: 2021-2030
* Dementia Drugs Market Segmentation By Drug Class: MAO Inhibitors, Glutamate Inhibitors, And Cholinesterase Inhibitors
* Dementia Drugs Market Segmentation By Indication: Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, And Others
* Dementia Drugs Market Segmentation By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, And Others
* Dementia Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
* Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Dementia Drugs market will grow by 2030? Click to get a snapshot of the Dementia Drugs Market Forecast [https://www.delveinsight.com/sample-request/dementia-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Dementia Drugs KOL - Views and Insights

To keep up with the Dementia Drugs market trends, we take KOLs and SME's opinions working in the Dementia Drugs domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging Dementia Drugs market trends. This will support the clients in making informed business decisions by identifying the overall scenario of the market and the unmet needs.

Reasons To Buy Dementia Drugs Market Report:

* The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Dementia Drugs Market.
* To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
* Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
* Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
* To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
* Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Which key players in the Dementia Drugs market are set to emerge as the trendsetter explore @ Dementia Drugs Market Landscape [https://www.delveinsight.com/sample-request/dementia-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Dementia Drugs Market Report Introduction

2. Dementia Drugs Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Dementia Drugs Market Key Factors Analysis

6. Dementia Drugs Market Porter's Five Forces Analysis

7. Dementia Drugs Market Layout

8. Dementia Drugs Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-dementia-drugs-market-size-to-grow-at-a-cagr-of-8-by-2030-evaluates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting



This release was published on openPR.